Viyash Scientific Ltd

Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 19 Jan 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Viyash Scientific Ltd experienced a significant intraday decline on 2 Mar 2026, touching a low of Rs 195.7, down 7.97% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and subdued market sentiment within the Pharmaceuticals & Biotechnology space.

Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook.

Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 February 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

Viyash Scientific Ltd has delivered an outstanding financial performance in the December 2025 quarter, marking a significant improvement in key metrics such as revenue growth, profitability, and operational efficiency. This robust quarter contrasts with the company’s previous trend and positions it favourably within the Pharmaceuticals & Biotechnology sector, despite a recent dip in share price and broader market volatility.

Viyash Scientific Ltd. (formerly Sequent Scientific Ltd.), a leading integrated pharmaceutical company operating in animal health APIs and formulations, reported its Q3 FY26 results with consolidated net profit declining 29.99% quarter-on-quarter to ₹38.44 crores, despite revenue reaching an all-time high of ₹858.41 crores. The stock, trading at ₹200.85 with a market capitalisation of ₹9,121 crores, has declined 3.92% following the results announcement, reflecting investor concerns over profit volatility and stretched valuations at 206x P/E ratio.

Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sequent Scientific Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and robust quarterly financial results. The upgrade, effective from 19 Jan 2026, is underpinned by a combination of enhanced technical trends, strong profit growth, rising promoter confidence, and a valuation that, while expensive, is supported by recent performance metrics.

Sequent Scientific Ltd has seen its investment rating downgraded from Hold to Sell as of 13 January 2026, reflecting a complex interplay of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly results and rising promoter confidence.

Sequent Scientific Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish trend to a sideways movement. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s mixed technical signals across weekly and monthly charts suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Sequent Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sequent Scientific Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 02 Sep 2025. While this rating change occurred in early September, the analysis and financial metrics discussed here reflect the company’s current position as of 30 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a nuanced shift in its technical momentum as recent evaluation adjustments reflect a transition from a bullish to a mildly bullish trend. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a multifaceted picture of the stock’s near-term trajectory.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting evolving price momentum and mixed signals from key indicators such as MACD, RSI, and moving averages. The stock’s recent price movements and technical trends offer a nuanced picture for investors analysing its near-term trajectory.

Sequent Scien., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by contrasting performance indicators across quality, valuation, financial trends, and technical parameters.